Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.
View stock
VS
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
View stock

Stock highlights

Stock comparison highlights
Stock name
Minerva Neurosciences IncEli Lilly
Last price
$2.38$1,427.28
Currency
USD
USD
$124M$1.3T
-46.65
-$8.44$30.81
0.010.39
0$6.69
00.48%
Sector
HealthHealth
Employees
750,000
Ticker
$NERV$LLY
Primary listing
NASDAQNYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in $NERV or $LLY on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.